Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note published on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on ATYR. HC Wainwright reaffirmed a buy rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Thursday, August 15th. Royal Bank of Canada reissued an outperform rating and set a $16.00 price objective on shares of Atyr PHARMA in a report on Wednesday, August 14th.

Atyr PHARMA Price Performance

NASDAQ ATYR opened at $1.88 on Thursday. The company has a current ratio of 7.63, a quick ratio of 7.63 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $129.74 million, a price-to-earnings ratio of -2.09 and a beta of 1.22. The company’s 50-day moving average is $1.87. Atyr PHARMA has a fifty-two week low of $1.08 and a fifty-two week high of $2.50.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, equities analysts expect that Atyr PHARMA will post -0.94 EPS for the current year.

Insider Buying and Selling

In related news, Director Paul Schimmel bought 41,052 shares of Atyr PHARMA stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average cost of $1.74 per share, with a total value of $71,430.48. Following the purchase, the director now owns 354,075 shares in the company, valued at $616,090.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.70% of the stock is currently owned by company insiders.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.